Full SPaeDD Ahead
Advances in pediatric drug development have been slow. We can do better if we collaborate.
Andrew Parker | | Opinion
It’s true what they say about strength in numbers; pooling both resources and expertise allows those collaborating to better tackle the challenges associated with complex research and development. The result is an approach greater than the sum of its parts.
In my view, collaboration is particularly crucial in areas of drug development with great unmet medical needs, such as the pediatric field. Over the past few decades, pediatric drug development has not kept up with the progress made by medicines tailored to adults, and there are many limitations that disincentivize companies from formulating medicines specifically for children. Children’s physiological make-up will alter as they age, with factors such as the composition of intestinal fluids, gut permeability and metabolism all changing over time. In addition, there is a distinct lack of methodologies and clear guidelines available to support pediatric medicine development.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.